Menu
Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS patients: A Randomized, Double-blind, Placebo-controlled clinical trial.
The purpose of this study is to examine whether use of a fixed dose of investigational product, GaRP, could improve Irritable Bowel Syndrome by at least a 20% improvement in the IBS-SSS score. The investigational product, GaRP is formulated from 5 natural ingredients to assist patients with chronic bowel conditions and associated symptoms.
To be eligible for this study, you will need to meet the following criteria:
If enrolled, your participation is expected to last approximately 12 weeks (3 months). The first 2 weeks is a baseline period where we ensure your eligibility. You then proceed to take the investigational product for 8 weeks followed by a 2-week washout/follow up period. If enrolled, you will be required to attend 4 on site visits and 4 fortnightly phone calls.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.
